Blackhawk’s MindBio Therapeutics Invests NZ$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials
MindBio Therapeutics invested NZ$2.3M to fast-track its research on microdosing LSD for depression and end-of-life distress in late-stage cancer patients.